Preclinical CROs Market

PRECLINICAL CRO SERVICES Market to 2031: Size, Share & Growth Report

The global preclinical CROs market is expected to value at USD 7.42 billion in 2026 and is projected to reach USD 11.05 billion by 2031, growing at a CAGR of approximately 8.3% during 2026–2031.

The preclinical CROs market growth is supported by sponsors shuttering in-house toxicology capacity in favor of asset-light R&D models even as regulators push the industry toward new, non-animal approach methodologies.   

The preclinical CROs market marks a shift in which drug sponsors increasingly treat early-stage safety and efficacy testing as a capability to outsource rather than own outright, even as pharmaceutical R&D budgets continue to grow and the regulatory definition of acceptable preclinical evidence itself is being rewritten.

For instance, according to the 2025 annual report of Pfizer, it committed ~USD 10.7 billion to USD 11.7 billion in R&D spending while simultaneously shuttering internal toxicology labs to redirect resources toward digital pathology capabilities, illustrating how even the largest sponsors are choosing to outsource capacity they once kept in-house rather than expand it internally.

Regulators are reinforcing this shift from the other direction. The FDA issued draft guidance in December 2025 on Monoclonal Antibodies. Streamlined Nonclinical Safety Studies, stating its belief that six-month nonhuman primate toxicity testing can be eliminated or reduced when supplemented with a weight-of-evidence risk assessment, and followed in March 2026 with broader draft guidance on General Considerations for the Use of New Approach Methodologies in Drug Development.

CROs are also under growing pressure from an entirely new source of scientific demand. Oncology sponsors increasingly need preclinical partners capable of testing next-generation modalities rather than conventional small molecules alone. At AACR 2026 in April, Crown Bioscience showcased integrated platforms specifically built to support antibody-drug conjugates and radiopharmaceuticals, reflecting how quickly preclinical service portfolios are being rebuilt around oncology's newest drug classes.

Top 10 Key Takeaways

• North America has the largest installed base, driven by concentrated biopharmaceutical R&D spending and the presence of the industry's largest integrated CROs.
• Asia Pacific is the fastest-growing region, propelled by expanding biotech research activity and cost-competitive toxicology and bioanalysis capacity across China and India.
• Toxicology testing leads by service share, reflecting its role as the most heavily regulated and consistently required preclinical service across nearly all drug programs.
• Patient-derived xenograft models lead by model-type share, though patient-derived organoid models are the fastest-growing model type as predictive efficacy data gains regulatory credibility.
• Biopharmaceutical companies remain the dominant end-user segment, while academic and research institutes are growing fastest as translational research funding expands.
• Sponsors are increasingly favoring asset-light R&D models, shuttering internal toxicology capacity in favor of CRO relationships that flex with pipeline demand.
• Regulatory momentum toward New Approach Methodologies is accelerating, with the FDA issuing consecutive draft guidance in December 2025 and March 2026 addressing non-animal safety assessment.
• The largest near-term opportunity is AI-enabled in-silico toxicology, which lets CROs compress study timelines and sponsor costs without waiting for full regulatory replacement of animal models.
• Oncology-focused CROs are expanding into antibody-drug conjugates and radiopharmaceutical safety testing as sponsor pipelines shift toward these next-generation modalities.
• The primary near-term restraint is the high cost and long timelines still associated with GLP-compliant toxicology studies for programs not yet eligible for streamlined pathways. 

Why the PRECLINICAL CROs Market Matters Now

Drug sponsors have historically maintained a mix of in-house toxicology and safety pharmacology capability alongside external CRO relationships, adequate when pipeline volumes were predictable and regulatory expectations for preclinical evidence remained stable for decades. Preclinical CRO platforms are absorbing a growing share of that work because both assumptions have broken down. Sponsors increasingly prefer variable, outsourced capacity over fixed internal infrastructure, and the regulatory definition of acceptable preclinical evidence is shifting quickly enough that few sponsors want to bet their own labs on any single methodology.

The market covers the contract research services used to support early-stage, pre-human drug development, spanning toxicology testing, bioanalysis and DMPK studies, safety pharmacology, and compound management and chemistry across patient-derived and traditional animal models. It includes large, integrated CROs offering discovery-through-IND services, and specialized providers focused on specific models or therapeutic areas such as oncology. The scope excludes clinical-stage CRO services covered under the broader clinical CRO market and drug discovery services that precede formal preclinical development. The market connects to the broader clinical CRO market, the drug discovery services market, and the in-vitro toxicology testing market.

The market's structure reflects a capability-versus-flexibility divide. The largest biopharmaceutical sponsors increasingly outsource even core toxicology work to integrated CROs such as Charles River Laboratories and Labcorp Drug Development, trading direct control for the flexibility to scale capacity up or down with pipeline volume. Mid-size biotechs and academic sponsors rely almost entirely on outsourced capability from the start, trading in-house expertise entirely for CRO partnerships across the full discovery-through-IND continuum. Oncology-focused sponsors sit alongside general biopharma as an increasingly distinct segment specifically seeking CROs with modern, patient-derived model capability rather than traditional animal models alone.

Market Trends Shaping PRECLINICAL CRO SERVICES MARKET

The key trend is sponsors shifting toxicology spend from internal labs to outsourced CRO capacity rather than expanding in-house infrastructure. Pfizer's decision to shutter internal toxicology labs while simultaneously committing ~USD 10.7 to 11.7 billion to R&D spending illustrates how even the largest, best-capitalized sponsors are treating outsourced preclinical capacity as the default rather than the exception.

Another trend is New Approach Methodologies moving from regulatory roadmap to actionable draft guidance. The FDA's April 2025 Roadmap to Reducing Animal Testing in Preclinical Safety Studies set direction, but its December 2025 draft guidance on monoclonal antibody nonclinical safety studies and March 2026 broader NAMs guidance are the first concrete steps translating that roadmap into specific, actionable sponsor recommendations.

A third trend is patient-derived models gaining share against traditional animal models. Patient-derived xenograft models already lead current model-type revenue share, while patient-derived organoid models are forecast to grow fastest as their predictive efficacy data gains increasing regulatory credibility alongside traditional approaches.

A fourth trend is AI and in-silico platforms becoming standard complements to wet-lab toxicology rather than a speculative future capability. Industry analysis increasingly treats machine-learning toxicology, including multivariate toxicity-fingerprint models trained on existing drug data, as tools already in active use for predicting safety endpoints ahead of or alongside physical studies.

The fifth trend sees oncology-focused CROs expanding into antibody-drug conjugates and radiopharmaceutical safety testing. Crown Bioscience's AACR 2026 showcase of integrated platforms built specifically for these next-generation modalities demonstrates how quickly preclinical oncology service portfolios are being rebuilt around where sponsor pipelines are actually heading.

Market Drivers Accelerating Growth

The first driver is the rising number of drugs entering preclinical pipelines across biologics and cell therapy. As sponsors expand pipeline complexity beyond traditional small molecules, they need considerably more specialized preclinical capability than a generalist internal toxicology function was ever designed to provide.

The second driver is sponsors shuttering in-house toxicology capacity in favor of asset-light R&D models, specifically because outsourced capacity flexes with pipeline volume in ways fixed internal infrastructure cannot. Pfizer's public disclosure of this strategy in its 2025 Form 10-K gives other sponsors considerably more confidence that outsourcing core toxicology work is a viable strategy rather than an admission of reduced capability.

The third driver is regulatory push toward New Approach Methodologies creating demand for specialized capability that most internal sponsor labs do not yet have. As the FDA's consecutive 2025 and 2026 draft guidance formalize expectations around weight-of-evidence assessments and in-silico tools, sponsors require CRO partners with considerably more validated NAM experience than building that capability internally would allow on a comparable timeline.

Market Restraints AND Challenges

The key restraint is the high cost and long timelines still associated with GLP-compliant toxicology studies for programs not yet eligible for streamlined pathways. Even as NAM-based approaches gain regulatory traction for select drug classes such as monoclonal antibodies, most preclinical programs still require full traditional toxicology packages, and that cost and timeline burden remains a genuine constraint on sponsor R&D budgets.

Another restraint is capacity constraints limiting CRO throughput during demand surges, which slows timelines specifically for sponsors without long-standing CRO relationships. Facilities managing surging biologics and cell therapy preclinical volume remain understandably constrained in how quickly they can onboard new sponsor programs, even where individual CRO platforms are technically capable of the work.

The third challenge involves validating non-animal methods to regulatory-grade reliability. With FDA guidance still in draft form for most NAM applications, sponsors and CROs face a genuine scientific and commercial challenge in determining how much reliance on in-silico or organoid-based data regulators will ultimately accept without supplementary animal data.

Report Scope

The preclinical CRO services market covers revenue generated by contract research organizations from outsourced, NAM-based preclinical testing, assay, and research services performed on behalf of sponsors to assess safety, efficacy, pharmacodynamics, ADME/DMPK, and chemical hazards. The scope also includes NAM method development, validation, and technology transfer services provided by CROs to sponsors. The market excludes revenue from the commercial sale of testing models, platforms, systems, or software as standalone products (captured under the NAMs product/technology market), and excludes conventional in-vivo animal study CRO revenue.

Market Segmentation

The preclinical CRO services market segments across four key dimensions. By service, the market covers pharmacology and efficacy services; DMPK/ADME and pharmacokinetics services; toxicology and safety assessment services; safety pharmacology services; bioanalytical and biomarker services; pathology services, including histopathology; research models and translational platform services; regulatory and IND/CTA-enabling services; and other services. By molecule type, the market includes small molecule, biologics, and medical devices. By therapeutic area, the market spans oncology, neurology, respiratory disorders, metabolic disorders/endocrinology, cardiovascular system disorders, dermatology, gastrointestinal, immunological disorders, infectious diseases, psychiatry, ophthalmology, genitourinary and women's health, and other therapeutic areas. By end user, it serves pharmaceutical companies, biotechnology and biopharmaceutical companies, medical device companies, and other end users.

Segment Insights

By service, the preclinical CRO services market is segmented into pharmacology and efficacy services, DMPK/ADME and pharmacokinetics services, toxicology and safety assessment services, safety pharmacology services, bioanalytical and biomarker services, pathology services (including histopathology), research models and translational platform services, regulatory and IND/CTA-enabling services, and other services. Toxicology and safety assessment services held the largest share of the market in 2025, driven by their mandatory role in regulatory submissions, the breadth of study types required across drug classes, and sponsors' continued reliance on CRO expertise to meet IND/CTA-enabling safety

By molecule type, the preclinical CRO services market is segmented into small molecule, biologics, and medical devices. Small molecule held the largest share of the market in 2025, supported by the high volume of small-molecule pipelines still in preclinical development, well-established outsourcing pathways, and the broader base of CROs offering small-molecule-specific testing capabilities.

By therapeutic area, the preclinical CRO services market is segmented into oncology, neurology, respiratory disorders, metabolic disorders/endocrinology, cardiovascular system disorders, dermatology, gastrointestinal, immunological disorders, infectious diseases, psychiatry, ophthalmology, genitourinary and women's health, and other therapeutic areas. Oncology held the largest share of the market in 2025, driven by the sheer volume of oncology pipeline candidates in preclinical development, high sponsor spending on specialized tumor models and efficacy testing, and the complexity of oncology-specific toxicology and biomarker work that favors outsourcing to specialized CROs.  

By end user, the preclinical CRO services market is segmented into pharmaceutical companies, biotechnology and biopharmaceutical companies, medical device companies, and other end users. Pharmaceutical companies held the largest share of the market in 2025, due to their extensive outsourcing of preclinical drug discovery, safety assessment, and IND-enabling testing to CROs across large and diversified pipelines.

By Region

North America

North America holds the largest base. The US leads with key CROs including Charles River Laboratories and Labcorp Drug Development, alongside deep biopharmaceutical R&D investment reflected in sponsors such as Pfizer redirecting internal toxicology spend toward outsourced capacity. Canada also contributes through growing contract research capacity supporting North American drug development.

Europe

Europe holds a substantial base. The UK and Germany spearhead European preclinical research through Eurofins Scientific's and Evotec's home-market presence. France contributes through ICON plc's expanding European footprint, while the broader region benefits from EU regulatory alignment with FDA-led New Approach Methodology initiatives.

Asia Pacific

Asia Pacific is the fastest-growing region. China spearheads regional growth through WuXi AppTec's and Medicilon's extensive discovery-through-IND service platforms, offering cost-competitive toxicology and bioanalysis capacity. India and South Korea advance through expanding biotech research activity and growing government investment in translational research infrastructure.

Latin America

The Latin America preclinical CRO services market grows steadily. Brazil leads the region due to its established network of contract research providers, expanding pharmaceutical research base, and increasing demand for in vitro and reconstructed tissue model testing services.  

Middle East and Africa

The Middle East and Africa market expands gradually. The Middle East is investing in biomedical research infrastructure as part of broader healthcare innovation strategies. Latin America contributes through growing contract research interest tied to expanding regional clinical and preclinical trial activity. 

Key Company Insights

The competitive landscape consists of four tiers: large integrated global CROs offering discovery-through-IND services, specialized oncology and model-focused providers, regional CROs concentrated in cost-competitive markets, and niche safety pharmacology and bioanalysis specialists. Major players include-

• Charles River Laboratories
• Labcorp Drug Development
• WuXi AppTec
• Eurofins Scientific
• ICON plc
• Evotec SE
• Medicilon
• Crown Bioscience
• Inotiv
• Champion Oncology
• Envigo (now part of Inotiv)
• SGS Life Sciences
• Pharmaron
• Altasciences

Charles River Laboratories leads through the scale and breadth of its integrated discovery-through-IND service platform, combining research models, toxicology, bioanalysis, and safety pharmacology into a single provider relationship that reduces the number of vendors sponsors must coordinate across a drug program.

WuXi AppTec has become a leading cost-competitive CRO platform through its extensive China-based discovery chemistry and toxicology capacity, giving sponsors an integrated alternative to Western providers for early-stage drug development services.

Crown Bioscience and Evotec SE each continue extending focused oncology and translational research expertise into specialized preclinical deployment, competing directly with larger integrated entrants for sponsor programs requiring patient-derived model capability.

Key company strategy conclusions:

• Charles River Laboratories and Eurofins Scientific are best positioned in the preclinical CRO services market through their large, integrated contract-testing operations, enabling them to offer bundled testing packages that combine multiple NAM-based and conventional methods for sponsors preferring to outsource across the full preclinical workflow.
• Certara and Simulations Plus support the market through in silico and PBPK modeling services, which benefit from the longest history of regulatory use among NAM categories and are increasingly offered as standalone or bundled preclinical service lines.

Recent Developments

• In April 2026, Crown Bioscience showcased integrated platforms at AACR 2026 enabling next-generation oncology modalities, including antibody-drug conjugates and radiopharmaceuticals, reflecting how quickly preclinical oncology service portfolios are being rebuilt around sponsors' newest drug classes.
• In March 2026, NIH announced its first USD 150 million in Complement-ARIE program awards to develop, implement, and standardize laboratory- and computer-based new approach methodologies.
• In July 2025, FDA and NIH co-hosted a workshop on reducing animal testing, after which NIH confirmed that new funding opportunities would no longer be developed exclusively around animal-only research designs.
• In April 2025, the FDA announced its “Roadmap to Reducing Animal Testing in Preclinical Safety Studies,” targeting monoclonal antibodies as the first drug class for phased replacement of routine animal testing with NAMs.

Real-World Use Cases

Pfizer's decision to shutter internal toxicology labs while redirecting resources toward digital pathology capabilities illustrates that the largest, best-resourced sponsors are treating outsourced preclinical capacity as a deliberate strategic choice rather than a cost-driven compromise. By maintaining ~USD 10.7 to 11.7 billion in overall R&D commitment while reducing owned infrastructure, Pfizer demonstrates a model other large sponsors are increasingly following, preserving R&D intensity while shifting the underlying execution to CRO partners better positioned to flex capacity with pipeline volume.

Crown Bioscience's AACR 2026 platform showcase shows how a specialized oncology CRO can scale from conventional in vivo oncology models into next-generation modality support without abandoning its core scientific identity. By building integrated platforms specifically for antibody-drug conjugates and radiopharmaceuticals, the company gives oncology sponsors a preclinical partner whose service portfolio evolves in step with where drug development is actually heading, rather than requiring sponsors to seek out entirely new CRO relationships for each emerging modality.

Conclusion and Future Outlook

Through 2031, preclinical CROs are expected to continue to reshape sponsors’ planning, execution, and validation of increasingly complex early-stage drug development programs. The forces driving the market- rising preclinical pipeline volume, sponsors shuttering in-house capacity, and regulatory momentum toward New Approach Methodologies, are compounding simultaneously with a new source of demand. AI-enabled in-silico platforms maturing enough to meaningfully compress study timelines without waiting for full regulatory replacement of traditional models. The next phase is expected to be hybrid preclinical programs, combining traditional toxicology, patient-derived models, and in-silico prediction into a single validated evidence package tailored to each drug's risk profile.

The competitive landscape will be defined by model diversity and regulatory science depth. Large integrated CROs compete against specialized oncology and model-focused providers for the same sponsor R&D budgets. For Chief Scientific Officers, VP Nonclinical Development leaders, and investors, organizations that partner with CROs offering validated NAM capability alongside traditional services will manage regulatory acceptance risk and study timelines more effectively than those relying on conventional animal-only testing programs in an increasingly NAM-oriented regulatory environment.

Frequently Asked Questions (FAQ)

1. How big is the preclinical CRO services market?

The preclinical CROs market was estimated at roughly USD 7.42 billion in 2026 and is projected to reach about USD 11.05 billion by 2031. North America accounts for the largest share, driven by concentrated biopharmaceutical R&D spending and the presence of the industry's largest integrated CROs.

2. What is the preclinical CRO services market growth rate?

The market is forecast to grow at a CAGR of approximately 8.3% from 2026 to 2031. Asia Pacific is the fastest-growing region, driven by expanding biotech research activity and cost-competitive capacity across China and India.

3. Which segment leads the preclinical CRO services market?

By service, toxicology testing leads the market, while safety pharmacology experiences the fastest growth. By model type, patient-derived xenograft models lead, though patient-derived organoid models show the fastest growth.

4. Who are the key players in the preclinical CRO services market?

Leading players include Charles River Laboratories, Labcorp Drug Development, WuXi AppTec, Eurofins Scientific, ICON plc, Evotec SE, Medicilon, Crown Bioscience, Inotiv, Champion Oncology, Envigo, SGS Life Sciences, Pharmaron, Altasciences, and Simtra BioPharma Solutions.

5. What are the factors driving the preclinical CRO services market?

The primary drivers are the rising number of drugs entering preclinical pipelines across biologics and cell therapy, sponsors shuttering in-house toxicology capacity in favor of asset-light R&D models, and regulatory push toward New Approach Methodologies.  

Speak With Our Analyst

The preclinical CROs market is where drug sponsor R&D strategy and regulatory science converge into a single early-stage development category, and the segment-level detail on service economics, model-type dynamics, end-user behavior, and competitive capability positioning is where strategic decisions are won or lost. MarketsandMarkets can help you go deeper: request a sample of the full study, speak with our analyst about your specific questions, or customize the scope to your target services, model types, and geographies. Reach out to explore how this intelligence can inform your R&D sourcing strategy, CRO selection, or investment thesis.